Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · Real-Time Price · USD
13.93
-0.29 (-2.04%)
May 28, 2025, 4:00 PM - Market closed
Cadrenal Therapeutics Employees
Cadrenal Therapeutics had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$3,208,365
Market Cap
27.40M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 1 | 33.33% |
| Dec 31, 2022 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CVKD News
- 13 days ago - Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
- 20 days ago - Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - Business Wire
- 5 weeks ago - Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - Business Wire
- 7 weeks ago - Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - Business Wire
- 2 months ago - Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Business Wire
- 3 months ago - Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - Business Wire
- 3 months ago - Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire
- 4 months ago - Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - Business Wire